What is the appropriate acute and long‑term management for a 73‑year‑old patient with overt hyperthyroidism, evidenced by a suppressed TSH (~0.15 mIU/L) and markedly elevated free T4 (~25 µg/dL) and free T3 (~6 µg/dL)?

Management of Overt Hyperthyroidism in a 73-Year-Old Patient

This 73-year-old patient with overt hyperthyroidism (suppressed TSH ~0.15 mIU/L, markedly elevated free T4 ~25 µg/dL, and elevated free T3 ~6 µg/dL) requires immediate beta-blocker therapy for symptom control, followed by definitive treatment with either antithyroid drugs, radioactive iodine, or surgery, with the choice depending on etiology and cardiovascular risk profile.

Acute Management

Immediate Symptom Control

• Initiate beta-blocker therapy immediately (atenolol 25-50 mg daily or propranolol, titrating for heart rate <90 bpm if blood pressure allows) for symptomatic relief of tachycardia, tremor, and anxiety 1.
• Provide hydration and supportive care 1.
• Given the patient's age (73 years), cardiovascular assessment is critical as untreated hyperthyroidism causes cardiac arrhythmias, heart failure, and increased mortality 2.

Severity Grading and Hospitalization Decision

• If the patient has severe symptoms (Grade 3-4): inability to perform activities of daily living, severe tachycardia, heart failure, or altered mental status, hospitalize immediately 1.
• For hospitalized patients, endocrine consultation should guide additional medical therapies including steroids, saturated solution of potassium iodide (SSKI), or thionamides (methimazole or propylthiouracil), and possible surgery 1.
• If symptoms are moderate (Grade 2): able to perform activities of daily living, outpatient management with close monitoring is appropriate 1.

Diagnostic Workup to Determine Etiology

Essential Testing

• Measure TSH receptor antibodies (TRAb) to identify Graves' disease, especially if there are clinical features like ophthalmopathy or T3 toxicosis 1.
• Perform thyroid scintigraphy if the etiology is unclear or if thyroid nodules are present on examination to differentiate between Graves' disease (diffuse uptake), toxic nodular goiter (focal uptake), or thyroiditis (low uptake) 3, 2.
• Physical examination should specifically assess for: diffuse goiter and thyroid bruit (Graves' disease), ophthalmopathy or exophthalmos (Graves' disease), or palpable nodules (toxic nodular goiter) 1, 2.

Long-Term Definitive Management

Treatment Selection Based on Etiology

For Graves' Disease:

• First-line treatment is a 12-18 month course of antithyroid drugs (methimazole preferred over propylthiouracil except in first trimester pregnancy or thyroid storm) 3, 2.
• Remission occurs in approximately 55% of patients after median 6.8 years of treatment, though some patients require life-long therapy 4.
• Radioactive iodine is preferred for definitive therapy in older adults, particularly those with cardiovascular comorbidities, as it is well-tolerated with the main long-term sequela being hypothyroidism 5.
• Long-term low-dose methimazole is a viable alternative to radioactive iodine in older adults 6.
• Surgery (near-total thyroidectomy) is reserved for large goiters causing compressive symptoms, refusal of radioactive iodine, or suspected malignancy 3, 5.

For Toxic Nodular Goiter:

• Radioactive iodine is the treatment of choice for toxic nodular goiter 5.
• Antithyroid drugs will not cure toxic nodular goiter but can be used for short-term control before definitive therapy 5.
• Surgery is indicated for large goiters (>40 g) causing compressive symptoms 4.

For Thyroiditis:

• Thyroiditis is self-limited and typically resolves in weeks with supportive care (beta-blockers only) 1.
• Monitor thyroid function every 2-3 weeks to catch transition to hypothyroidism, which is the most common outcome 1.
• Antithyroid drugs are not indicated as there is no increased thyroid hormone synthesis 3.

Special Considerations for Age 73

Cardiovascular Risk Management

• Subclinical hyperthyroidism with TSH <0.1 mIU/L should be treated in older adults due to associations with increased cardiovascular mortality, stroke, coronary heart disease, and heart failure 6.
• This patient has overt hyperthyroidism with even greater cardiovascular risk, making treatment mandatory 6, 2.
• Avoid over-replacement or under-replacement with thyroid hormone if the patient transitions to hypothyroidism, as both are associated with adverse cardiovascular and skeletal events in older adults 6.

Treatment Approach Modifications

• In older adults with multiple comorbidities or cardiac disease, radioactive iodine may be preferred over prolonged antithyroid drug therapy to achieve definitive control more rapidly 6.
• If antithyroid drugs are used, long-term low-dose methimazole is an acceptable alternative to radioactive iodine 6.
• Monitor for bone density loss, as hyperthyroidism and subclinical hyperthyroidism are associated with osteoporosis in older adults 2.

Monitoring Strategy

Short-Term Monitoring

• Repeat thyroid function tests (TSH, free T4, free T3) every 2-3 weeks initially to assess response to therapy and catch transition to hypothyroidism if thyroiditis is the cause 1.
• Monitor for symptom resolution and cardiovascular stability 1.

Long-Term Monitoring

• Once euthyroid on definitive therapy, monitor thyroid function every 6-8 weeks while titrating treatment 1.
• After achieving stable euthyroidism, repeat testing every 6-12 months or as indicated for symptom changes 1.
• If TRAb remains positive for >5 years (smoldering-type Graves' disease), life-long antithyroid drug treatment may be required 4.

Common Pitfalls to Avoid

• Do not delay beta-blocker initiation while awaiting definitive diagnosis, as symptom control is critical for cardiovascular protection in this age group 1.
• Do not use antithyroid drugs empirically without determining etiology, as they are ineffective and unnecessary for thyroiditis 3.
• Do not assume all hyperthyroidism in older adults is Graves' disease—toxic nodular goiter is common in this age group and requires different definitive management 1.
• Avoid radioactive iodine if Graves' ophthalmopathy is present without corticosteroid cover, as it may worsen eye disease 5.
• Do not discharge without ensuring close follow-up, as progression to thyroid storm is life-threatening 1.